Curasight
2,31
DKK
−20,07 %
CURAS
Spotlight Stock Market
Medical Equipment & Services
Health Care
Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer. Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.
Lue lisääViimeisimmät analyysit
Viimeisin analyysiraportti
Julkaistu: 07.05.2025
Pörssikalenteri
Osavuosikatsaus Q2'25
Osavuosikatsaus Q3'25
Curasight carries out a directed issue of shares to guarantors in connection with the completed rights issue
Curasight: Completed registration of rights issue
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
PREMIUM-tili
Resolutions of the Annual General Meeting 2025 of Curasight A/S
Curasight announces outcome in rights issue
Subscription of new shares in the Right Issue 2025 exercised by Curasight management
Curasight: Notice of Annual General Meeting 2025
Last day of the subscription period in Curasight's rights issue of shares
Curasight A/S selects CRO to run Phase 1 trial with uTREAT[®] in brain cancer
